Lyrica (pregabalin) is prescribed for nerve pain, fibromyalgia, and seizure disorders, but stopping it suddenly can trigger withdrawal symptoms ranging from anxiety and insomnia to seizures and suicidal thoughts. According to the FDA's official prescribing information, postmarketing reports of pregabalin discontinuation have documented seizures, depression, suicidal ideation and behavior, agitation, confusion, and psychotic symptoms among the reported withdrawal effects. This isn't rare internet speculation, it's in the drug's own federal labeling. Here's what the withdrawal timeline actually looks like, why it happens, and how to come off Lyrica safely.
If you're having thoughts of suicide or self-harm, the 988 Suicide and Crisis Lifeline is available 24/7 by call or text. Do not stop taking Lyrica abruptly without medical guidance.
Lyrica is the brand name for pregabalin, an anticonvulsant prescribed for nerve pain from diabetes or shingles, fibromyalgia, seizure disorders, and other neuropathic pain. It works by calming overactive nerve signals in the central nervous system. Over time, the brain adapts to its presence, which can lead to tolerance and physical dependence, even when the medication is taken exactly as prescribed. Pregabalin is classified as a Schedule V controlled substance in the United States due to its potential for misuse.
Because pregabalin affects the nervous system in ways similar to alcohol and benzodiazepines, case reports in the clinical literature suggest a comparable withdrawal mechanism: discontinuation disrupts the balance of GABA, a calming neurotransmitter the brain has adjusted its production of during regular use. When the medication is removed too quickly, that adjustment hasn't had time to reverse, producing the rebound symptoms associated with withdrawal.
The FDA's prescribing information for Lyrica lists the following as reported postmarketing withdrawal symptoms following pregabalin discontinuation:
- Seizures
- Depression and suicidal ideation or behavior
- Agitation, confusion, and disorientation
- Psychotic symptoms
- Anxiety and insomnia
- Nausea, pain, and diarrhea
- Sweating, tremor, headache, and dizziness
Case reports published in clinical literature have also documented more severe reactions in some individuals, including hallucinations, delirium, and, in rare cases, self-harm. Symptom severity tends to track with dose and duration of use, longer-term or higher-dose use is associated with more intense withdrawal.
Pregabalin has a short half-life of roughly 5.5 to 6.7 hours, which is part of why withdrawal can begin quickly. Based on FDA labeling and published case reports:
- 24 to 48 hours after the last dose: Initial withdrawal symptoms typically begin, sometimes within one to two days of a missed or reduced dose.
- First week: Symptoms are usually most intense during this period.
- Following weeks: Acute symptoms generally resolve, though residual anxiety, insomnia, or mood changes can persist for several weeks in some individuals.
Notably, research has found that withdrawal symptoms can occur even after relatively short-term use, one case series identified withdrawal after as little as two months of regular use, and even in people without a prior psychiatric history. This isn't limited to long-term or high-dose use, though both increase the risk.
The FDA specifically advises tapering pregabalin gradually over a minimum of one week rather than stopping abruptly. A supervised taper reduces the intensity of withdrawal and lowers the risk of the more serious complications, seizures, dehydration from vomiting or diarrhea, and the psychiatric symptoms including suicidal ideation documented in postmarketing data. Attempting to self-taper without medical guidance removes that safety margin, particularly given how quickly and unpredictably symptoms can escalate.
Professional detox provides 24/7 medical supervision during the highest-risk withdrawal window. Physicians may use supportive medications to manage specific symptoms during a taper, such as agents to manage agitation and blood pressure, anti-seizure medication if needed, and supportive care for nausea or sleep disruption, always under direct medical supervision rather than self-directed use. No single standardized medication protocol exists specifically for pregabalin discontinuation, which is exactly why medical oversight, not a self-managed taper, is the safer path.
Detox addresses the physical withdrawal process, but ongoing treatment matters for preventing relapse. Effective follow-up care often includes individual therapy, group therapy, relapse prevention counseling, and psychiatric care for co-occurring anxiety or depression. When mental health conditions are present alongside pregabalin dependence, integrated dual diagnosis treatment tends to produce better outcomes than treating either issue separately.
Frequently asked questions
According to FDA prescribing information, reported symptoms include anxiety, insomnia, sweating, nausea, headache, depression, agitation, and in more serious cases, seizures and suicidal ideation. Severity varies by dose and duration of use.
Symptoms typically begin within 24 to 48 hours of the last dose, peak during the first week, and largely resolve within days to a few weeks. Some residual symptoms like anxiety or sleep disruption can persist longer in certain individuals.
Yes. Abrupt discontinuation can trigger seizures and serious psychiatric symptoms, including documented cases of suicidal ideation. The FDA specifically recommends tapering gradually over a minimum of one week under medical supervision rather than stopping abruptly.
Yes. Case reports have documented withdrawal symptoms after as little as two months of regular use, even in people with no prior psychiatric history, though longer-term or higher-dose use is generally associated with more severe symptoms.
Pregabalin is classified as a Schedule V controlled substance in the United States due to documented potential for misuse, and long-term use can lead to physical dependence even when taken exactly as prescribed.
A gradual, medically supervised taper, ideally over a minimum of one week as recommended in FDA labeling, with a physician monitoring for withdrawal symptoms and adjusting the pace as needed. Self-tapering without medical guidance removes that safety oversight.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: September 2026
Related articles
Resources
